BIOCAD
https://biocadglobal.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BIOCAD
Keytruda Cements Cervical Cancer Leadership With First-Line Nod
Although the label’s PD-L1 expression requirement could limit the addressable market, there is also potential for future combination with Seagen’s recently approved Tivdak.
Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice